DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “World
Anxiety Disorders and Depression Treatment Market – Opportunities and
Forecasts, 2014 – 2022” report to their offering.
Depression and anxiety disorders are the most common psychiatric
disorders affecting a huge population across the globe. Depression; is
related to a state of emotion that further affects actions, thoughts and
sometimes the sleeping pattern of the concerned person.
Depression is the most common type of mental disorder affecting nearly
350 million patients of varied scale age groups, whereas, anxiety is a
reaction to stress. Extreme level of anxiety result in anxiety disorders
which include phobias, obsessive-compulsive disorder, panic disorder,
post-traumatic based stress disorder.
The rising geriatric population, reduced side effects and greater
efficacy of new/innovative drugs along with the accelerating prevalence
of anxiety depression disorders are contributing towards the growth of
this market. However, patent expiry for majority of the drugs, dry
pipeline for the novel drugs, mental disorders that are drug-resistant
and growing numbers of different generic drugs are analysed to impede
the anxiety disorders and depression treatment market growth. The
prospect of innovations and developments in herbal remedies with an
improved distribution network is offers potential opportunities for the
- Eli Lilly and Company
- Forest Laboratories, Inc.
- AstraZeneca PLC
- Merck Co., Inc.
- Pfizer, Inc.
- GlaxoSmithKline plc
- Johnson Johnson
For more information about this report visit http://www.researchandmarkets.com/research/c88g8f/world_anxiety